KALA BIO, Inc.

KALA BIO, Inc. is a clinical-stage biopharmaceutical company headquartered in Arlington, Massachusetts, dedicated to the research, development, and commercialization of innovative therapies for rare and severe diseases of the eye. The company's mission involves leveraging its proprietary mesenchymal stem cell secretome (MSC-S) platform to develop novel biologics. In a strategic pivot, KALA BIO is also developing an enterprise AI tool, Researgency.ai, to optimize clinical research outcomes by enhancing access to and analysis of clinical trial data.

KALA BIO's primary product candidate is KPI-012, a human MSC-S therapy currently in clinical development for treating persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The company is also exploring KPI-012 for other rare corneal conditions, such as Limbal Stem Cell Deficiency, and has preclinical development underway for KPI-014, targeting inherited retinal diseases. Beyond its biologics pipeline, KALA BIO offers an AI platform-as-a-service through Researgency.ai, designed to provide secure, purpose-built AI systems for biopharmaceutical clients.

In recent leadership changes, Avi Minkowitz was appointed Chief Executive Officer and Chief Financial Officer of KALA BIO, Inc. effective February 2, 2026. The company has recently launched its Bionic Intelligence Research Agent (BIRA) via the Researgency.ai platform, marking a significant step in its dual strategy to combine its biologics pipeline with an AI platform-as-a-service. KALA BIO also settled approximately $10.6 million of debt in December 2025, positioning itself for future growth in both biopharmaceutical development and AI infrastructure for the biotech industry.